|
1
|
Narlik-Grassow M, Blanco-Aparicio C and
Carnero A: The PIM family of serine/threonine kinases in cancer.
Med Res Rev. 34:136–159. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ren K, Gou X, Xiao M, Wang M, Liu C, Tang
Z and He W: The over-expression of Pim-2 promote the tumorigenesis
of prostatic carcinoma through phosphorylating eIF4B. Prostate.
73:1462–1469. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Asano J, Nakano A, Oda A, Amou H, Hiasa M,
Takeuchi K, Miki H, Nakamura S, Harada T, Fujii S, et al: The
serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in
myeloma cells. Leukemia. 25:1182–1188. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kapelko-Słowik K, Urbaniak-Kujda D,
Wołowiec D, Jaźwiec B, Dybko J, Jakubaszko J, Słowik M and
Kuliczkowski K: Expression of PIM-2 and NF-κB genes is increased in
patients with acute myeloid leukemia (AML) and acute lymphoblastic
leukemia (ALL) and is associated with complete remission rate and
overall survival. Postepy Hig Med Dosw (Online). 67:553–559. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ramachandran J, Santo L, Siu KT, Panaroni
C and Raje N: Pim2 is important for regulating DNA damage response
in multiple myeloma cells. Blood Cancer J. 6:e4622016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu Z, Liu H, Yuan X, Wang Y, Li L, Wang
G, Song J, Shao Z and Fu R: Downregulation of Pim-2 induces cell
cycle arrest in the G0/G1 phase via the p53-non-dependent p21
signaling pathway. Oncol Lett. 15:4079–4086. 2018.PubMed/NCBI
|
|
7
|
Ren K, Zhang W, Shi Y and Gong J: Pim-2
activates API-5 to inhibit the apoptosis of hepatocellular
carcinoma cells through NF-kappaB pathway. Pathol Oncol Res.
16:229–237. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Corey SJ, Minden MD, Barber DL, Kantarjian
H, Wang JC and Schimmer AD: Myelodysplastic syndromes: The
complexity of stem-cell diseases. Nat Rev Cancer. 7:118–129. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nimer SD: MDS: A stem cell disorder-but
what exactly is wrong with the primitive hematopoietic cells in
this disease? Hematology Am Soc Hematol Educ Program. 43–51. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Boissel N, Nibourel O, Renneville A,
Gardin C, Reman O, Contentin N, Bordessoule D, Pautas C, de Revel
T, Quesnel B, et al: Prognostic impact of isocitrate dehydrogenase
enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: A
study by the acute leukemia french association group. J Clin Oncol.
28:3717–3723. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Thol F, Weissinger EM, Krauter J, Wagner
K, Damm F, Wichmann M, Göhring G, Schumann C, Bug G, Ottmann O, et
al: IDH1 mutations in patients with myelodysplastic syndromes are
associated with an unfavorable prognosis. Haematologica.
95:1668–1674. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Patnaik MM, Hanson CA, Hodnefield JM,
Lasho TL, Finke CM, Knudson RA, Ketterling RP, Pardanani A and
Tefferi A: Differential prognostic effect of IDH1 versus IDH2
mutations in myelodysplastic syndromes: A mayo clinic study of 277
patients. Leukemia. 26:101–105. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ramachandran N and Colman RF: Chemical
characterization of distinct subunits of pig heart DPN-specific
isocitrate dehydrogenase. J Biol Chem. 255:8859–8864.
1980.PubMed/NCBI
|
|
14
|
Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang
P, Yu W, Li Z, Gong L, Peng Y, et al: Glioma-derived mutations in
IDH1 dominantly inhibit IDH1 catalytic activity and induce
HIF-1alpha. Science. 324:261–265. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dolcet X, Llobet D, Pallares J and
Matias-Guiu X: NF-kB in development and progression of human
cancer. Virchows Arch. 446:475–482. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang G, Sai K, Gong F, Yang Q, Chen F and
Lin J: Mutation of isocitrate dehydrogenase 1 induces glioma cell
proliferation via nuclear factor-κB activation in a
hypoxia-inducible factor 1-α dependent manner. Mol Med Rep.
9:1799–1805. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tong H, Hu C, Zhuang Z, Wang L and Jin J:
Hypoxia-inducible factor-1alpha expression indicates poor prognosis
in myelodysplastic syndromes. Leuk Lymphoma. 53:2412–2418. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Arber DA, Orazi A, Hasserjian R, Thiele J,
Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M and Vardiman JW:
The 2016 revision to the world health organization classification
of myeloid neoplasms and acute leukemia. Blood. 127:2391–2405.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nakagawa T, Matozaki S, Murayama T,
Nishimura R, Tsutsumi M, Kawaguchi R, Yokoyama Y, Hikiji K, Isobe T
and Chihara K: Establishment of a leukaemic cell line from a
patient with acquisition of chromosomal abnormalities during
disease progression in myelodysplastic syndrome. Br J Haematol.
85:469–476. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Harper JW, Elledge SJ, Keyomarsi K,
Dynlacht B, Tsai LH, Zhang P, Dobrowolski S, Bai C, Connell-Crowley
L, Swindell E, et al: Inhibition of cyclin-dependent kinases by
p21. Mol Biol Cell. 6:387–400. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gartel AL, Serfas MS and Tyner AL:
p21-negative regulator of the cell cycle. Proc Soc Exp Biol Med Soc
Exp Biol Med. 213:138–149. 1996. View Article : Google Scholar
|
|
23
|
Lin CC, Hou HA, Chou WC, Kuo YY, Liu CY,
Chen CY, Lai YJ, Tseng MH, Huang CF, Chiang YC, et al: IDH
mutations are closely associated with mutations of DNMT3A, ASXL1
and SRSF2 in patients with myelodysplastic syndromes and are stable
during disease evolution. Am J Hematol. 89:137–144. 2014.
View Article : Google Scholar : PubMed/NCBI
|
